MONTREAL, QUEBEC--(Marketwire - July 12, 2010) - A5 Labs (OTCBB: AFLB) is pleased to announce that it has completed the acquisition of the Contract Research (CRO) and Interferon production technology announced on May 7, 2010. The company plans to immediately secure the intellectual property related to the interferon production technology as well as complete its plans for pilot scale production and commercialization of interferon products for veterinary and human applications.
In addition, with the acquisition of the CRO assets, the company has established the capacity for contract analytical, product development, regulatory and testing services in the pharmaceutical and environmental sector.
“We are very pleased to complete the acquisition of the CRO and Interferon production technology assets. We now have at our disposal the necessary assets to develop and commercialize novel biotechnology products,” said Dr. Richard Azani, President and CEO.
About A5 Labs:
A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5’s products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5’s expansion efforts, economic conditions in the industry and the financial strength of A5’s customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
Contacts:
A5 Laboratories Inc.
Investor Relations
1-877-331-8777
ir@a5labs.com
